Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron Pharmaceuticals

3 Biotech Stocks Set to Revolutionize Medicine

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

StockNews.com

3 Biotech Stocks That Could Deliver Big Gains

The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of new therapeutics, and increased R&D spending on treatments for new and rare diseases. Hence, investors should consider strong biotech stocks such as Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which could deliver big…

StockNews.com

Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling

Tesla led the S&P 500 index on Monday, moving toward a buy point. Regeneron Pharmaceuticals tumbled on a surprise court ruling.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

How Is Regeneron Pharmaceuticals' Stock Performance Compared to Other Biotechnology Stocks?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.

Barchart

Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms

Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.

Investors Business Daily

Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised

The Dow fell after initially rising on the PPI inflation report on the stock market today. Analysts hiked Microsoft and Nvidia price targets.

Investors Business Daily

Plunge into Profits With These 3 Biotech Stocks

The biotech industry's robust growth potential is driven by substantial pharma research and development, swift technological advancements, and lucrative government support. Given this backdrop, quality biotech stocks ProQR Therapeutics N.V. (PRQR), Regeneron Pharmaceuticals (REGN), and Corcept Therapeutics (CORT) could be solid buys now. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High

Regeneron Pharmaceuticals put up a commanding fourth-quarter beat on Friday, helped by Praluent. REGN stock is trading at an all-time high.

Investors Business Daily

Regeneron surpasses Q4 revenue expectations with strong results

Regeneron Pharmaceuticals surpasses expectations with strong fourth-quarter revenue, boosting investor confidence in the company's performance.

Top News

Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise

Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers

Regeneron Pharmaceuticals topped third-quarter forecasts on Thursday, helped by a strong launch from its high dose of Eylea. REGN stock rose.

Investors Business Daily

Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) has an impressive revenue and earnings surprise history. So, as the company gears up to post its third-quarter report, is REGN the right pick? Read on.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Regeneron Bulls, Bears Clash: Will Biotech Get Eylea Mojo Back?

With Regeneron earnings due Nov. 2, the big debate is whether the company will get its mojo back in its core eye disease treatment business?

Investors Business Daily

Regeneron Pharmaceuticals Stock Earns 85 RS Rating

A Relative Strength Rating upgrade for Regeneron Pharmaceuticals shows improving technical performance.

Investors Business Daily

Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough'

Shares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals' high-dose Eylea following a delay this summer.

Investors Business Daily

IBD Screen Includes Meta, Tesla, Other Big Techs, But These Others Are In Buy Zones

This stock screener identified 26 stocks that mutual funds are adding. We highlight seven familiar names with several in buy zones.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Biotech Stocks With 'A' POWR Ratings

The biotech industry is poised for significant growth due to the rising orphan drug formulations and the adoption of emerging technologies. Therefore, fundamentally strong biotech stocks Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and United Therapeutics (UTHR) might be solid buys. These stocks are A (Strong Buy) rated in our proprietary…

Investors Business Daily

Regeneron Sacrifices A Breakout As Competition Hammers At Its Biggest Moneymaker

The struggles continued for Regeneron's blockbuster eye disease treatment, Eylea, in the first quarter — leading REGN stock to dive Thursday.

Investors Business Daily

Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin

Regeneron Pharmaceuticals said sales of its linchpin Eylea drug have been negatively impacted by a short-term shift to rival drug Avastin.

Investors Business Daily

Dexcom Leads 5 Stocks Near Buy Points

Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals.

Investors Business Daily

Regeneron Sinks Despite Massive Earnings Beat On A Notable Blockbuster Miss

Regeneron Pharma topped third-quarter expectations Thursday, reporting less of a decline than expected. But REGN stock was down early.

Benzinga

Regeneron Pharmaceuticals Unusual Options Activity

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange trades.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022

Upgrades

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations